Cite
HARVARD Citation
Tannir, N. et al. (2021). Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. International journal of cancer. 149 (2), pp. 403-408. [Online].